Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation

研究成果: Review article同行評審

16 引文 斯高帕斯(Scopus)

摘要

Clostridium difficile infection (CDI) remains a major public health issue, and fecal microbiota transplantation (FMT) has become one of the standard therapies for recurrent or refractory CDI. When compared to medical therapies, such as metronidazole or vancomycin, FMT has a high rate of treatment response with acceptable safety and efficiency. Following promulgation of the amendments in September 2018 in Taiwan, FMT has been indicated for recurrent or refractory CDI. The Taiwan Microbiota Consortium contributed to the Taiwan FMT Expert Consensus, which established basic norms and stipulated essential principles, including the indications for transplantation, eligible locations and personnel, donor screening policies, fecal sample handling, and post-FMT follow-up. However, establishing an eligible FMT team in a qualified hospital remains a clinical challenge, and the requirement for facilities and well-screened donors impedes the implementation of FMT. In this review, we aim to provide domestic FMT teams with explicit instructions to facilitate realization and increase the practice of FMT. Based on the Taiwan FMT Expert Consensus and current regulations, we performed a literature review and integrated the experiences of Taiwanese multidisciplinary experts into this article. The content intends to offer clinicians up-to-date evidence and highlight the essential points of FMT.

原文English
頁(從 - 到)841-850
頁數10
期刊Journal of Microbiology, Immunology and Infection
52
發行號6
DOIs
出版狀態Published - 2019 12月

All Science Journal Classification (ASJC) codes

  • 免疫學和過敏
  • 一般免疫學和微生物學
  • 微生物學(醫學)
  • 傳染性疾病

指紋

深入研究「Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation」主題。共同形成了獨特的指紋。

引用此